DEXCOM INC - FORM 10-Q - XML - IDEA: XBRL DOCUMENT - May 2, 2012

Attached files
FileFilename
EX-32.01 - CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO 18 U.S.C. SECTION 1350 - DEXCOM INCd330251dex3201.htm
XML - IDEA: XBRL DOCUMENT - DEXCOM INCR26.htm
10-Q - FORM 10-Q - DEXCOM INCd330251d10q.htm
XML - IDEA: XBRL DOCUMENT - DEXCOM INCR20.htm
XML - IDEA: XBRL DOCUMENT - DEXCOM INCR27.htm
XML - IDEA: XBRL DOCUMENT - DEXCOM INCR10.htm
XML - IDEA: XBRL DOCUMENT - DEXCOM INCR5.htm
XML - IDEA: XBRL DOCUMENT - DEXCOM INCR21.htm
XML - IDEA: XBRL DOCUMENT - DEXCOM INCR16.htm
XML - IDEA: XBRL DOCUMENT - DEXCOM INCR14.htm
XML - IDEA: XBRL DOCUMENT - DEXCOM INCR13.htm
XML - IDEA: XBRL DOCUMENT - DEXCOM INCR15.htm
XML - IDEA: XBRL DOCUMENT - DEXCOM INCR19.htm
XML - IDEA: XBRL DOCUMENT - DEXCOM INCR23.htm
XML - IDEA: XBRL DOCUMENT - DEXCOM INCR11.htm
XML - IDEA: XBRL DOCUMENT - DEXCOM INCR12.htm
XML - IDEA: XBRL DOCUMENT - DEXCOM INCR4.htm
XML - IDEA: XBRL DOCUMENT - DEXCOM INCR18.htm
XML - IDEA: XBRL DOCUMENT - DEXCOM INCR1.htm
XML - IDEA: XBRL DOCUMENT - DEXCOM INCR17.htm
XML - IDEA: XBRL DOCUMENT - DEXCOM INCR3.htm
XML - IDEA: XBRL DOCUMENT - DEXCOM INCR7.htm
XML - IDEA: XBRL DOCUMENT - DEXCOM INCR24.htm
XML - IDEA: XBRL DOCUMENT - DEXCOM INCR22.htm
XML - IDEA: XBRL DOCUMENT - DEXCOM INCR6.htm
XML - IDEA: XBRL DOCUMENT - DEXCOM INCR2.htm
XML - IDEA: XBRL DOCUMENT - DEXCOM INCR8.htm
XML - IDEA: XBRL DOCUMENT - DEXCOM INCR31.htm
XML - IDEA: XBRL DOCUMENT - DEXCOM INCR30.htm
XML - IDEA: XBRL DOCUMENT - DEXCOM INCR29.htm
EXCEL - IDEA: XBRL DOCUMENT - DEXCOM INCFinancial_Report.xls
XML - IDEA: XBRL DOCUMENT - DEXCOM INCR9.htm
XML - IDEA: XBRL DOCUMENT - DEXCOM INCR25.htm
EX-32.02 - CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO 18 U.S.C. SECTION 1350 - DEXCOM INCd330251dex3202.htm
EX-31.02 - CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO SECURITIES EXCHANGE ACTRULE - DEXCOM INCd330251dex3102.htm
EX-31.01 - CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO SECURITIES EXCHANGE ACTRULE - DEXCOM INCd330251dex3101.htm
v2.4.0.6
Development Agreements (Details) (USD $)
 3 Months Ended 0 Months Ended 3 Months Ended 3 Months Ended 0 Months Ended 3 Months Ended 0 Months Ended 1 Months Ended 0 Months Ended
Mar. 31, 2012
Mar. 31, 2011
Mar. 31, 2011
Animas Corporation [Member]
Jan. 31, 2009
Animas Corporation [Member]
Jan. 31, 2008
Animas Corporation [Member]
May 05, 2009
Edwards Lifesciences LLC [Member]
Mar. 31, 2012
Edwards Lifesciences LLC [Member]
Mar. 31, 2011
Edwards Lifesciences LLC [Member]
Dec. 31, 2010
Edwards Lifesciences LLC [Member]
Dec. 31, 2009
Edwards Lifesciences LLC [Member]
Nov. 30, 2008
Edwards Lifesciences LLC [Member]
Mar. 31, 2012
Roche Diagnostics Operations [Member]
Feb. 01, 2012
Tandem Diabetes Care, Inc. [Member]
D
Mar. 31, 2012
Tandem Diabetes Care, Inc. [Member]
Jul. 31, 2009
Maximum [Member]
Animas Corporation [Member]
May 05, 2009
Maximum [Member]
Edwards Lifesciences LLC [Member]
Nov. 01, 2011
Maximum [Member]
Roche Diagnostics Operations [Member]
Feb. 01, 2012
Maximum [Member]
Tandem Diabetes Care, Inc. [Member]
Nov. 01, 2011
Agreements With Roche Diagnostics Operations [Member]
Roche Diagnostics Operations [Member]
Nov. 01, 2011
Agreements With Roche Diagnostics Operations [Member]
Maximum [Member]
Roche Diagnostics Operations [Member]
Dec. 31, 2010
Manufacturing Line [Member]
Animas Corporation [Member]
May 31, 2011
Regulatory Body Approval [Member]
Animas Corporation [Member]
Feb. 01, 2012
Initial Payment [Member]
Tandem Diabetes Care, Inc. [Member]
Development Agreements [Line Items]                                              
Joint commitment to offset development, clinical and regulatory expenses       $ 300,000 $ 500,000       $ 10,000,000 $ 10,000,000 $ 13,000,000       $ 1,100,000 $ 10,000,000 $ 1,000,000 $ 1,000,000          
Joint commitment upfront fee           13,000,000                                  
Development grant and other revenue 1,477,000 1,035,000 25,000       300,000 600,000       47,000   57,000                  
One-time milestone payment, pending                                     500,000       100,000
One-time milestone payment, received                                         1,000,000 4,000,000  
Additional payment received upon agreement of a development and regulatory plan                         900,000           500,000        
Maximum number of days additional payment is to be made upon execution of agreement, days                         30                    
Development payment                                           300,000  
Profit-sharing percent maximum           10.00%                                  
Commercial sales royalty maximum           6.00%                                  
Additional milestone payments                         2,000,000             2,000,000      
Money eligible to be received related to regulatory approvals and manufacturing readiness             $ 12,000,000                                

User Contributions:

Comment about this document or add new information about this topic:

CAPTCHA


This web site and associated pages are not associated with, endorsed by, or sponsored by DEXCOM INC and has no official or unofficial affiliation with DEXCOM INC


Based on public records. Inadvertent errors are possible.
Faqs.org does not guarantee the accuracy or timeliness of any information on this site.  Use at your own risk. This website is not associated with the SEC

Some parts © 2013 Advameg, Inc.